Contents

for authors

Cart

quick search

Journal Info

  • Editor in Chief: Prof. Giovanni Gambaro
  • Co-Editor: Benedetta Bussolati
  • Current issue: Vol. 26 issue 6 , 2013 (November-December)

Contents

for authors

Cart

Your cart is empty

View cart

quick search

Vol. 23 Issue 4 (July-August 2010)

The effect of n-3 fatty acids on levels of methylarginines in patients with end-stage renal disease

The effect of n-3 fatty acids on levels of methylarginines in patients with end-stage renal disease

J Nephrol 2010; 23(4): 459 - 464

Article Type: ORIGINAL ARTICLE

Authors

My Svensson, Ole Frøbert, Erik B. Schmidt, Kaj A. Jørgensen, Ulf Simonsen, Jeppe H. Christensen

Abstract

Background: Patients with end-stage renal disease (ESRD) have a very high mortality mainly caused by cardiovascular disease (CVD). It has been suggested that plasma concentrations of asymmetric dimethyl arginine (ADMA), an endogenous nitric oxide synthase inhibitor, are markedly elevated in patients with ESRD. Elevation of ADMA is linked to CVD and an adverse prognosis. Supplementation with n-3 fatty acids has previously been shown to prevent CVD, but there is very little data regarding the effect of n-3 fatty acids on levels of ADMA. Methods: Patients with ESRD and documented CVD were randomized to treatment with 1.7 g of n-3 fatty acids (n=103, 34% women) or olive oil (n=103, 38% women) for three months. ADMA, symmetric dimethyl arginine (SDMA), L-arginine, and the relative content of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in serum phospholipids were measured before and after treatment. Results: ADMA was normally distributed with a mean value of 0.56±0.13 μmol/L (range 0.21-1.01) and only 14/206 (6.8 %) had elevated levels of ADMA. SDMA was generally elevated with a mean value of 1.88±0.64 μmol/L (range 0.67-4.56). Supplementation with n-3 fatty acids for three months did not change plasma levels of ADMA, SDMA or L-arginine. Conclusions: The present data do not support a beneficial effect of n-3 fatty acids on methylarginines in patients with ESRD.

Article History

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

Authors

  • Svensson, My [PubMed] [Google Scholar]
    Department of Nephrology, Skejby Hospital, Aarhus University Hospital, Aarhus - Denmark
  • Frøbert, Ole [PubMed] [Google Scholar]
    Department of Cardiology, Örebro University Hospital, Örebro and Department of Pharmacology, University of Aarhus, Aarhus - Denmark
  • Schmidt, Erik B. [PubMed] [Google Scholar]
    Department of Cardiology, Center for Cardiovascular Research, Aalborg Hospital, Aarhus University Hospital, Aalborg - Denmark
  • Jørgensen, Kaj A. [PubMed] [Google Scholar]
    Department of Nephrology, Skejby Hospital, Aarhus University Hospital, Aarhus - Denmark
  • Simonsen, Ulf [PubMed] [Google Scholar]
    Department of Pharmacology, University of Aarhus, Aarhus - Denmark
  • Christensen, Jeppe H. [PubMed] [Google Scholar]
    Department of Nephrology, Aalborg Hospital, Aarhus University Hospital, Aalborg - Denmark

This article is available as full text PDF.

No supplementary material is available for this article.